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The platinum-based drug cisplatin is a widely used ﬁrst-line therapy for several cancers.
Cisplatin interacts with DNA mainly in the form of Pt-d(GpG) di-adduct, which stalls cell
proliferation and activates DNA damage response. Although cisplatin shows a broad spec-
trum of anticancer activity, its utility is limited due to acquired drug resistance and toxicity to
non-targeted tissues. Here, by integrating genome-wide high-throughput Damage-seq, XR-
seq, and RNA-seq approaches, along with publicly available epigenomic data, we system-
atically study the genome-wide proﬁles of cisplatin damage formation and excision repair in
mouse kidney, liver, lung and spleen. We ﬁnd different DNA damage and repair spectra
across mouse organs, which are associated with tissue-speciﬁc transcriptomic and epige-
nomic proﬁles. The framework and the multi-omics data we present here constitute an
unbiased foundation for understanding the mechanisms of cellular response to cisplatin. Our
approach should be applicable for studying drug resistance and for tailoring cancer che-
motherapy regimens.
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C isplatin, a platinum (Pt) coordination complex, is one ofthe most effective chemotherapeutic drugs used to treatseveral cancers, including testicular, ovarian, cervical,
head, neck, non-small-cell lung cancer, and colorectal cancer1–4.
Despite the fact that cisplatin can bind a wide range of cellular
components, including proteins, RNA, membrane phospholipids,
microﬁlaments, and thiol-containing peptides, DNA is con-
sidered a major target for cisplatin2. Once inside cells, cisplatin
undergoes aquation, and the platinum atom of cisplatin binds
covalently to the N7 position of purines resulting in about 65%
GpG, 25% ApG 1,2-intra-strand crosslinks, and ~5–10% GpNpG
1,3- intra-strand crosslinks, as well as a lower percentage of inter-
strand crosslinks5. In response to cisplatin, cells activate multiple
repair pathways, among which nucleotide excision repair pathway
constitutes the main mechanism to detect and repair cisplatin-
induced DNA adducts6–8. Two major nucleotide excision repair
pathways, transcription-coupled repair (TCR) and global repair
(GR), are well known to remove cisplatin-induced DNA adducts.
TCR acts on the transcribed strands (TS) of active genes, while
GR acts on the non-transcribed region of the genome, as well as
the non-transcribed strands (NTS) of transcribed genes9.
Although cisplatin shows a broad spectrum of anticancer
activity, its utility is limited due to acquired drug resistance and
serious side effects. Cisplatin resistance, which often results in
disease recurrence, originates from multiple cellular self-defence
adaptations, including reduced uptake and increased drug efﬂux,
inactivation by proteins (e.g., metallothionein), small molecules
(e.g., glutathione), and increased damage repair or tolerance1,10.
In addition, common side effects associated with cisplatin treat-
ment are ototoxicity, peripheral neuropathy, myelosuppression,
and nephrotoxicity11. Another limitation in the use of cisplatin is
damage to non-targeted tissues, suggesting that long-term off-
target effects induced by the chemotherapeutic drugs are one of
the major factors causing mortality in cancer survivors in later
stage of life12.
Since the discovery of cisplatin in the early 1960’s, considerable
efforts have been made to increase its anti-cancer drug efﬁciency
and meanwhile to minimize its side effects to normal tissues13. A
major barrier to a comprehensive understanding of the under-
lying molecular mechanism that related cisplatin-induced drug
resistance and side effects is, however, a lack of approach that
allows precise and high-resolution measurements of the genome-
wide cisplatin-induced damage and repair in a high-throughput
manner. Furthermore, most of the data from existing studies were
generated using isolated cell lines, which can be misleading when
extending the application to the in vivo experiments and clinical
trials14.
Here, we adopted high-throughput Damage-seq, eXcision
Repair-seq (XR-seq), and RNA-seq to generate an integrated map
of DNA damage, repair, and gene expression at single-nucleotide
resolution across four mouse organs. Our experimental and
analytical framework presented in this study serve as a resource
for researchers interested in DNA damage and repair associated
with cisplatin treatment in mouse models. Our analysis of the
high-throughput data from the in vivo experiments shed lights
upon not only the mechanisms of cisplatin-induced DNA-
damage and repair, but also the cytotoxicity and drug resistance,
both of which are important for chemotherapy regimens. The
data we generated provide a platform for further research on
optimizing cisplatin treatment efﬁcacy and reducing side effects.
Results
Overview. In this work, we present an experimental and analy-
tical framework where we systematically assay and proﬁle DNA
damage, excision repair, and gene expression in a genome-wide
fashion across four mouse organs. Figure 1a outlines the experi-
mental design. Speciﬁcally, cisplatin was administered by an
intraperitoneal injection in mice. DNA damage, excision repair,
and gene expression were measured after 4 h cisplatin treatment
by damage sequencing (Damage-seq)15, excision repair sequen-
cing (XR-seq)16, and RNA sequencing (RNA-seq), respectively.
All experiments were performed with two biological replicates.
Genome-wide DNA damage, excision repair, and gene expression
data show that samples from the same organs are clustered
together by both principal component analysis (PCA) (Fig. 1b)
and hierarchical clustering using the pairwise Euclidean distance
between samples (Supplementary Figure 1). In addition, we
retrieved publicly available epigenomic proﬁles across the four
organs by ChIP-seq (H3K4me1, H3K4me3, H3K27ac,
H3K27me3, H3K36me3, and POLR2A) and DNase-seq (DNase I
hypersensitivity site) from the ENCODE Project. All of the
ENCODE epigenetic data were generated from mice without
cisplatin treatment, and represent overall organ-speciﬁc chro-
matin states, transcription factor binding, and histone modiﬁca-
tions patterns17. Refer to Materials and Methods for details on
experimental design and data processing. In the following sec-
tions, we describe how Damage-seq and XR-seq data are quan-
tiﬁed and normalized, how gene expression is evaluated by RNA-
seq, and then compare and contrast relationships between DNA
damage, repair, RNA expression, and epigenetic markers.
Cisplatin-induced DNA damage maps across mouse organs.
Here, we adopted a previously developed high-throughput
sequencing protocol, Damage-seq15, for assaying genome-wide
DNA damage with single base pair resolution. Damage-seq has
been successfully applied to map DNA damage caused by cis-
platin18 and ultraviolet radiation15 onto the human genome
in vitro. In this study, we applied Damage-seq to generate
genomic proﬁles of cisplatin-induced DNA damage across four
mouse organs (Supplementary Data 1). GG (Guanine-Guanine
dinucleotide) is enriched 1–2 bp upstream of the 5′-end of the
reads across all samples, indicating adequate data quality (Sup-
plementary Figure 2). Notably, while we do not observe other
dinucleotide enrichment, there is a preference for adenine 5′ to
the GG dinucleotides of our Damage-seq reads (Supplementary
Figure 3). Refer to Materials and Methods for details on library
preparation, sequencing, and bioinformatic analysis.
Damage-seq measures the overall damage induced by cisplatin
minus the accumulated excision repair from 0 to T = 4 h after
cisplatin treatment by TCR in the TS and the GR in the TS and
NTS:
Damage TS ¼
XDamage
Z T
0
GRTSt dt 
Z T
0
TCRtdt;
DamageNTS ¼
XDamage
Z T
0
GRNTSt dt:
ð1Þ
For data normalization, we ﬁrst adjusted for the sequencing
depth by dividing the total read counts by a sample-speciﬁc
library size factor. Then, we adjusted for the number of GG
dinucleotide sequences in each gene. We found that the number
of GG dinucleotide sequences in the TS and NTS are highly
correlated across all genes (r= 0.99, Supplementary Figure 4)
and since cisplatin mainly induces Pt-d(GpG) damage, this
achieves better normalization results than adjusting for the
gene lengths, as shown in Supplementary Figure 5. After data
normalization, we found that across all samples and organs, the
damage level from the TS was lower than that from the NTS,
due to ongoing TCR on the transcribed strand for 4 h until the
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data were collected (Supplementary Figure 6). We then applied
PCA to the normalized read count matrix from the NTS, where
a negligible fraction of total DNA damage is repaired by GR
only (Refer to Section “Effect of transcription on damage
formation and repair” for more details). We found that samples
from the same organ are clustered together, indicating organ-
speciﬁc DNA damage at 4 h (Fig. 1b). This was further
conﬁrmed by hierarchical clustering on the pairwise Euclidean
distance between the samples (Supplementary Figure 1c) using
highly variable genes.
We further investigated the Pt-d(GpG) di-adduct formation
efﬁciency across all organs both in silico and in vivo and found
that cisplatin induces DNA damage at different rates, with kidney
being the highest and spleen the lowest (Supplementary
Figure 7a). For in silico inference, we ﬁrst compared the NTS
reads from Damage-seq for each sample to a pseudo reference
constructed across all samples with adjustment of library size
factor and then inferred the relative DNA damage. Our in vivo
immuno-slot blot analysis, which detects unrepaired damage in
the genome, conﬁrmed that kidney is a major site of cisplatin
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Fig. 1 Overview of experimental design. a Outline of the experimental design. Cisplatin was administered by intraperitoneal injection in mouse. DNA
damage, excision repair, and gene expression were assayed by Damage-seq, XR-seq, and RNA-seq. b PCA reveals tissue-speciﬁc damage, repair, and
transcription across four mouse organs. All experiments were performed with two biological replicates
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DNA-adduct formation, followed by liver and lung, while spleen
is a minor site for cisplatin-induced DNA-adduct formation
(Supplementary Figure 7b). These results are consistent with what
has been reported in various studies of cisplatin DNA-adduct
formation using different approaches in the rodent model
system19–21. We further investigated the damage in mitochon-
drial DNA and found that in addition to nuclear DNA,
mitochondrial DNA is a major target of cisplatin (Supplementary
Figure 8), which is consistent with a previous report22 and is
possibly due to the lack of DNA excision repair in the
mitochondria23.
Cisplatin-induced DNA repair maps across mouse organs. To
reconstruct genome-wide DNA repair maps, XR-seq libraries for
cisplatin damage were prepared by adapting the XR-seq method
previously developed16. Speciﬁcally, the 21- to 31- nucleotide-
long oligomer products generated by nucleotide excision repair
were captured by IP and ligated to adaptors on both ends. The
ligation products were then puriﬁed by IP with the anti-cisplatin
antibody, and the Pt adducts were reversed by incubation with
NaCN. Finally, the oligomers were ampliﬁed to generate a library
which was sequenced. XR-seq has been successfully adapted to
assay genome-wide excision repair with single-nucleotide reso-
lution in human16, mouse24, plant25, bacteria26, and yeast27. In
this study, we applied XR-seq to quantify DNA excision repair in
four mouse organs after cisplatin treatment (Supplementary
Data 1), each with two biological replicates. Lengths of the excised
oligomers fall within the range of the 21–31 nucleotide (nt) with a
median of 26–27 nt (Supplementary Figure 9). As a target of
cisplatin, GG dinucleotides are enriched 5–8 nt upstream of the
3′-end of the reads across all samples (Supplementary Figures 10
and 11), which is consistent with previous high-resolution study
that mapped cisplatin damage and repair in cultured mammalian
cells18.
Unlike Damage-seq, XR-seq offers a snapshot of the ongoing
excision repair (XR), which includes both TCR and GR on the
transcribed strand and GR on the non-transcribed strand at time
T= 4h:
XR TS ¼ GRTST þ TCRTST
XRNTS ¼ GRNTST :
ð2Þ
In a similar fashion to Damage-seq, read counts from XR-seq
were normalized to adjust for biases introduced by sample-
speciﬁc sequencing depth and gene-speciﬁc number of GG
dinucleotides. After data normalization, we found that, across all
samples and organs, there is higher excision repair in the TS
compared to the NTS, due to TCR speciﬁc to the TS
(Supplementary Figure 12). PCA analysis on the normalized
read count matrix also shows organ-speciﬁc excision repair
patterns (Fig. 1b, Supplementary Figure 1b). For the mitochon-
drial DNA, we found on average 5.4% of the reads contain GG
dinucleotide, compared to a proportion of 73.2% for the non-
mitochondrial DNA (Supplementary Data 1). The greater
amount of background noise in mitochondria implies a lack of
excision repair in the mitochondrial DNA23.
Cisplatin-induced gene expression across mouse organs. RNA-
seq is fundamental for better understanding of transcriptomic
dynamics in cells and tissues under different conditions28,29. To
investigate the mechanistic link between cisplatin-induced DNA
damage, repair, and gene transcription regulation and to idenﬁty
cisplatin-induced gene expression patterns, we adopted RNA-seq
to perform transcriptomic proﬁles of mouse organs with or
without cisplatin treatment (Fig. 1a). We used reads per kilo base
per million reads (RPKM) for data normalization, COMBAT30
for batch correction, and DESeq231 for differential expression
analysis.
We found 1475, 364, 1122, and 193 signiﬁcantly up- and
downregulated genes in kidney, liver, lung, and spleen,
respectively (Supplementary Figure 13, Supplementary Data 2).
Downregulated genes were more prevalent compared to
upregulated genes, implying a cisplatin-related global tran-
scription repression. Across all organs, 3 genes are signiﬁcantly
upregulated, while 12 genes are signiﬁcantly downregulated
(refer to Fig. 2 for Venn diagram of genes with signiﬁcant
differential expression across the four organs). Among the
upregulated genes, Cdkn1a (P21) is a cyclin-dependent kinase
inhibitor and a target gene of P53, which inhibits both cell
cycle progression and replication under stress condition32;
PER1 is a core circadian clock factor that plays essential role
in the molecular clock mechanism33. Among the down-
regulated genes, DOCK1 and DENND1A proteins belong
to small GTPase signal transduction regulatory pathway, while
the rest play a role in fundamental cellular processes34,35.
Cisplatin-induced DNA damage causes a variety of cellular
responses (e.g., replication arrest, transcription inhibition, cell
cycle arrest, DNA repair, and apoptosis) and activates multiple
signal transduction pathways36. To gain insight into the functions
of the differentially expressed genes, we carried out gene ontology
(GO) analysis across mouse organs. Results from the GO analysis
revealed that a large subset of the differentially expressed genes in
kidney, liver, and lung after cisplatin treatment are primarily
involved in fundamental cellular processes such as regulation of
cell cycle, regulation of localization, metabolic process regulation,
cellular response to external and endogenous stimuli, cellular
communication and signaling, and subcellular component move-
ment (Supplementary Figure 14). Interestingly, in addition to
Per1 being signiﬁcantly upregulated across all organs, we found
upregulated genes in kidney (Csnk1e, Atf4, Hnrnpu, Bhlhe40,
Ddx5, Nﬁl3, Id1, Crem, Noct, Impdh2, Mybbp1a, Csnk1d, Sirt1,
Bhlhe41, Klf10, Cdk5r1, Sik1, Adamts1, Crem, Egr1 and Adrm1)
and lung (Ddx5, Id1, Fas, Ciart, Sirt1, Klf9, Sik1, Adamts1, and
Fzd4) were enriched in circadian rhythm and rhythmic process in
GO annotation. We did not ﬁnd statistically signiﬁcant enrich-
ment of genes listed under circadian rhythm in GO annotation in
liver or spleen. However, in addition to Per1, both Klf10 and Klf9
also demonstrated increased expression in liver, while Sik1 and
Klf9 exhibited increased expression in spleen. Our results agree
with previous ﬁndings that cellular DNA damage response is
closely linked to circadian clock regulation21,37.
To identify biological signaling pathways that are regulated
after cisplatin treatment, we further carried out Ingenuity
Pathway Analysis (IPA) on signiﬁcantly up- and downregulated
genes (adjusted t-test p-value less than 0.05 and absolute log
fold change >2). We identiﬁed signiﬁcantly regulated pathways
across organs, as reported in Supplementary Data 3, and found
that the ATM (ataxia-telangiectasia mutated protein) signaling
pathway was among the most signiﬁcantly upregulated path-
ways in kidney, liver, and lung. This result is consistent with
our ﬁnding that p53 signaling-related genes were enriched in
kidney, liver, and lung in our GO term analysis (Supplementary
Figure 14). In addition, protein kinase A (PKA) signaling,
synaptic long-term depression, and cardiac hypertrophy
signaling pathways were downregulated across all organs. The
PKA signaling pathway mediates diverse cellular processes,
including growth, development, memory, and metabolism.
Interestingly, it has been shown that inactivation of PKA
signaling results in increased DNA repair and resistance to
cisplatin38.
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Effect of transcription on damage formation and repair. To
study the effect of transcription on cisplatin-induced DNA
damage and excision repair, we used our RNA-seq data to seg-
regate genes based on their expression quantiles in the cisplatin-
treated group and investigated how DNA damage and excision
repair change in the TS and NTS as a function of gene expression
(Fig. 3). Our results show that, on the global scale, the damage
level in the NTS was roughly uniform, and is independent of the
gene expression level, due to the fact that GR in the NTS only
affects a small fraction of the overall accumulated damage. For
the damage level in the TS; however, we found that the remaining
damage at 4 h after cisplatin injection decreases as gene expres-
sion (or equivalently, transcription-coupled repair) increases and
is less than that in the NTS on the global scale (Fig. 3,
Supplementary Figure 6). The magnitude of difference between
the two depends on the TCR and thus the gene expression.
Furthermore, assuming that the proportion of damage repaired
by GR is negligible compared to the total induced damage, we
have:
R
TCRtdtP
Damage
 1DamageTS=DamageNTS: ð3Þ
Our results indicate that liver has the highest repair efﬁciency
by repairing the highest proportion of damage out of the total
(Supplementary Figure 15) and that the overall accumulated
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damage is driven by repair efﬁciency instead of damage
formation.
Globally, we ﬁnd that the excision repair measured by XR-seq
in the TS increased with gene expression, but plateaued among
highly expressed genes, potentially due to total repair saturation
(Fig. 3). For the NTS, we found that there was less repair
compared to the TS (Fig. 3, Supplementary Figure 12), and that
the repair in the NTS increased at a lower rate by expression
without saturation (Fig. 3), which can be explained by the open
chromatin nature of the active genes.
Effect of epigenomic proﬁles on damage formation and repair.
Packaging DNA into nucleosomes or higher order chromatin
structure prevents repair machinery from accessing damaged
DNA, which can result in differences in DNA-damage repair
kinetics39. We hypothesize that chromatin structure, in addition
to transcriptional rate, might be the rate-limiting factor for TCR.
Recent studies have shown that the efﬁciency of TCR of UV-
induced cyclobutene (CPDs) and (6-4) pyrimidine–pyrimidone
photoproducts (repaired by nucleotide excision repair) is closely
associated with chromatin states40. In order to further investigate
the effect of chromatin states, transcription factor binding, and
histone modiﬁcations on the damage formation and excision
repair, we retrieved the publicly available epigenomic proﬁles for
mouse kidney, liver, lung, and spleen from the ENCODE data-
base17. Supplementary Table 1 speciﬁes the bed ﬁles that we
downloaded, which contain genome-wide measurements of
average intensities for each chromosomal region for H3K4me1,
H3K4me3, H3K27ac, H3K27me3, H3K36me3, and POLR2A
markers by ChIP-seq, as well as DNase I hypersensitivity sites by
DNase-seq.
As a sanity check, we ﬁrst investigated the relationship between
expression and epigenomic markers in the control samples. We
found that H3K27me3 is negatively correlated with the expres-
sion, while all other epigenomic proﬁles are positively correlated,
as expected (Supplementary Figure 16). We further inferred the
relationship between transcription, DNA damage and repair, and
epigenomic proﬁles by studying the non-induced genes (i.e.,
genes that do not show differential gene expression after cisplatin
treatment) in each organ. Our results show that excision repair in
the TS is positively correlated with gene expression, H3K4me3,
and DNase I markers across all organs, while the damage in the
TS is negatively correlated with the aforementioned epigenetic
markers (Supplementary Figure 17). We did not observe
signiﬁcant correlations, in the same directions across all organs,
between the damage level in the NTS and the epigenetic markers.
This further supports the fact that damage is relatively uniformly
distributed along the genome (Supplementary Figure 17).
To compare across different organs, we ﬁrst identiﬁed organ-
speciﬁc gene expression using RNA-seq data for both cisplatin-
treated and control samples. For simplicity and without loss of
generality, we focus on comparing liver against the other organs
from this point on. Speciﬁcally, we carry out pairwise differential
expression analysis using DESeq2, which compares liver with
each of the other organs. The intersection of the signiﬁcant genes
from the pairwise comparisons is shown in Supplementary
Figure 18. For the genes that are signiﬁcantly highly and lowly
expressed in liver compared to the other organs, we further
investigated their organ-speciﬁc DNA damage, excision repair,
and epigenomic proﬁles (Fig. 4).
Speciﬁcally, for the 602 genes that are highly expressed in liver
(Fig. 4a), we found that TCR is higher in liver, reﬂected by higher
excision repair in the TS. GR is also higher in liver compared to
other organs, possibly due to a greater number of active genes
with open chromatin regions, as indicated by the epigenomic
markers (Fig. 4a). Notably, TCR removes DNA adducts at a much
higher rate than GR, resulting in a lower amount of damage in the
TS, while the overall accumulated damage in the NTS doesn’t
differ between organs (Fig. 4a). For the 414 genes that are lowly
expressed in liver (Fig. 4b), we observed low repair in TS and NTS
in liver and no signiﬁcant difference in the remaining damage
level across different organs (Fig. 4b). H3K4me1, H3K4me3,
H3K27ac, and H3K36me3 are markers of gene activation17,41 and
are correlated with high excision repair (Fig. 4a). On the other
hand, H3K27me3, a marker of inactive genes41, is higher for
genes with lower expression and excision repair (Fig. 4b). DNase I
hypersensitivity, which marks the regions of open chromatin17, is
higher for both highly and weakly expressed genes (Fig. 4a, b).
So far, we have focused on gene-speciﬁc measurements of gene
expression, DNA damage, excision repair, and chromatin states.
We further carried out genome-wide analysis of DNA damage
and repair, with association of different chromatin states. The
chromatin states, shown in Fig. 4c, are derived from histone
modiﬁcations and genomic sequence elements, with functional
roles inferred of each state42. We found that, similar to previous
results18, DNA repair is higher in active chromatin states such as
active promoters and CpG islands, the latter of which are
enriched at transcription start sites (Fig. 4c). The distribution of
the damage, on the other hand, with some minor differences, is
rather uniform (Fig. 4c). The differences in damage frequency
that we observe can potentially be attributed to differences in
DNA repair and number of GG dinucleotides.
Finally, as an example, we focused on chromosome 11, which
carries the Per1 gene that is upregulated across all organs after
cisplatin treatment (Fig. 5). As apparent from the high-resolution
data that Pt-d(GpG) damage distribution on NTS was uniform
among the different organs. In contrast, the repair efﬁciency on
the TS is associated with TCR (shown as strong XR-seq signal on
TS), and results in less Pt-d(GpG) damage on the TS. For repair,
the region with high levels of initial repair and low levels of
damage on the TS exhibited H3K4me3 or DNase I sensitivity
(Fig. 5). Note that the damage level is affected by the cisplatin
delivery efﬁciency (Supplementary Figure 7) and thus kidney has
a slightly higher damage level, shown in Fig. 4. We further
normalize the XR-seq and Damage-seq data by taking the ratio,
TS/(TS+NTS), and obtain the same results (Supplementary
Figure 19). Altogether, our data reveal that transcriptomic and
epigenomic proﬁles are associated with excision repair and can
thus recapitulate the genome-wide damage and repair proﬁles.
Discussion
Understanding the details of how cisplatin and other platinum
compounds activate cellular DNA damage responses and repair
signaling transduction will help us develop new strategies to
improve chemotherapeutic efﬁciency. Among the different DNA
damage response pathways, nucleotide excision repair pathway
constitutes the main mechanism to detect and repair cisplatin-
induced DNA adducts6. Although the machineries and regulatory
mechanisms of nucleotide excision repair are relatively well-
known7,43,44, the effect of transcriptomic and epigenomic proﬁles
on DNA damage and repair in a tissue-speciﬁc manner is at early
stage of investigation.
We have recently developed high-throughput sequencing
methods to assay genome-wide DNA damage formation and its
repair with single-nucleotide resolution, namely, Damage-seq and
XR-seq. Damage-seq has been successfully applied to measure
cisplatin- and ultraviolet-induced DNA damage in cultured
human cell lines15,18; XR-seq has been successfully adapted to
assay genome-wide excision repair in bacteria, plant, yeast,
mouse, and human18,25–27. To our best knowledge, this is the ﬁrst
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study that quantiﬁes cisplatin-induced DNA damage and repair
across mouse organs between cases and controls on the genome-
wide scale. We further combined Damage-seq and XR-seq with
RNA-seq and created a comprehensive “omics” resource of DNA
damage, repair, and gene expression across mouse organs. It is
noteworthy that the inherent heterogeneity of tissue samples from
mouse kidney, liver, lung, and spleen makes our measurements
potentially biased as attenuated means across different cell types.
Cell-type-speciﬁc DNA damage and repair within an organ are
hard to assay. This is due to the technical and technological
limitation in identifying constituent cell types in a heterogeneous
tissue and gaining enough cell-type-speciﬁc excision oligos before
they get degraded. As such, in this study we have resorted to
“bulk” RNA-seq, XR-seq, and Damage-seq, while to develop
high-throughput single-cell assay of DNA damage and repair is
one of the future directions for this study and can be of great
impact.
Our data show that cisplatin-induced DNA damage and repair
patterns are associated with multiple factors, including
transcription and chromatin states. Genome-wide Damage-seq
and XR-seq data reveal that the damage formation is globally
uniform and that the overall accumulated damage effect is driven
by not damage formation but repair efﬁciency (Fig. 3). This
ﬁnding is consistent with our previous high-resolution study that
mapped cisplatin damage in cultured mammalian cells18. In
addition, our data showed that the rate of excision repair on the
TS and NTS of active genes is positively correlated with gene
expression—the repair in the TS and NTS increases with gene
expression and plateaus in the TS among the highly expressed
genes (Fig. 3). Our data also suggest that cellular transcription
process also stimulates repair of damage in the NTS due to the
fact that transcription is associated with open chromatin con-
formation and hence increased accessibility to the repair
machinery (Figs. 3 and 4). These ﬁndings are consistent with
earlier results obtained using a primer extension technique in S.
cerevisiae45, and results from high-resolution repair maps of UV-
induced DNA damages (6-4-photoproducts and CPD) in cultured
human cells16.
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Fig. 4 Association of DNA damage and repair with gene expression and chromatin states. a A total of 602 genes that are highly expressed in liver show
higher transcription-coupled repair (in TS) and global repair (in NTS). Expression levels for these genes are also correlated with ChIP-seq signals for
histone modiﬁcation markers (H3K4me1, H3K4me3, H3K27ac, and H3K36me3). b A total of 414 genes that are lowly expressed in liver have lower repair
and are characterized by H3K27me3, a marker for gene inactivation. Chromatin accessibility (DNase I hypersensitivity site) is higher for both groups of
genes in a and b, indicating a role of chromatin states in transcriptional regulation. Median fold change (fc) between liver and the other organs across all
signiﬁcant genes is included on the upper right corner within each panel. cWhole-genome analysis results of DNA damage and repair in liver, with different
genomic annotations. Analysis of repair (left) and damage (right) levels across nine genomic annotations for mouse liver reveals uniform distribution of
damage but higher repair in active promotor, CpG island (enriched at transcription start sites), transcription elongation and transition regions in genome
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It is well documented that the acquisition of cisplatin resistance
in cancer cells is a complicated process, where increased damage
repair efﬁciency, reduced drug uptake, and increased drug efﬂux
may potentially play a role. Our results show that spleen has the
lowest amount of accumulated DNA damage induced by cisplatin
(Supplementary Figure 7). GO enrichment analysis indicates that
most of the downregulated genes in spleen belong to cell mem-
brane organization, membrane invagination, cellular response to
metal ion, and ferric iron transport by GO annotations. Previous
studies have shown that deletion of Ctr1 (copper transporter) in
both yeast and mouse cells causes a decrease in intracellular
cisplatin levels, suggesting a connection between cellular copper
and cisplatin transport46. We found that Atp7b and Steap3, two
genes that play a role in iron and copper homeostasis, were
downregulated in response to cisplatin treatment in spleen.
ATP7B is a copper-transporting P-type ATPase, which is asso-
ciated with cisplatin transport across the plasma membrane and
across the cell47. Overexpression of ATP7B is associated with
resistance of various cancer cells to platinum drugs by increasing
drug efﬂux1,48. We found that Atp7b expression is decreased
(four fold) in spleen after being treated with cisplatin, although
the exact mechanism, by which Atp7b is downregulated in spleen,
is not clear.
In addition to nuclear DNA damage, the cellular mitochondrial
DNA is also a target of cisplatin, suggesting that mitochondrial
DNA damage may contribute towards cisplatin-induced cell
death. Furthermore, it has been reported that the cisplatin ana-
logue oxaliplatin relies on a different mechanism—ribosome
biogenesis stress—to kill cancer cells, suggesting that a different
mechanism exists in addition to DNA-damage response to induce
cell death between platinum-like chemotherapeutic drugs49.
Given this aspect, studying the mechanisms behind the coordi-
nation of nuclear and mitochondrial DNA damage and repair
may be of future interest by means of improving drug efﬁcacy
while reducing side effects to normal tissues.
Here, we present a comprehensive genome-wide study of DNA
damage and excision repair across four mouse organs and
investigate their associations with transcription and chromatin
states, which serves as resource for researchers interested in DNA
damage and repair in mouse models. This framework can be
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ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08290-2
8 NATURE COMMUNICATIONS |          (2019) 10:309 | https://doi.org/10.1038/s41467-019-08290-2 | www.nature.com/naturecommunications
readily applied to other studies with a focus on chemical per-
turbations, drug resistance, and optimization of cancer che-
motherapy regimens.
Methods
Animal experiments. Six or seven-month-old wild-type (C57BL/6J) female mice
weighing 25–28 g were purchased from the Jackson Laboratory (Bar Harbor, ME).
Without further indications, mice were maintained under a 12-h light/12-h dark
regimen. All animal care and handling were performed according to the NIH and
the University of North Carolina School of Medicine (Institutional Animal Care
and Use Committee) rules for animal protection. Unless otherwise noted, all mice
were treated with drug at ZT1 (8 am) and killed at ZT5 (12 pm). A single non-
lethal dose of clinical cisplatin (1 mg/ml or 3.3 mM/L, by Fresenius Kabi) was
administered by intraperitoneal injection at 10 mg cis-DDP/Kg body weight. We
chose 10 mg/Kg dose to ensure sufﬁcient Pt-DNA adducts formation for detecting
genome-wide damage and repair by Damage-seq and XR-seq methods. This dose
has been routinely used in studies with the mouse strain C57BL/6J and is shown to
be well tolerated by the strain50. We followed this common practice and in
agreement with previous studies, we observed no morbidity or mortality for the
duration of our experiment and for at least 10 days following the administration of
the cisplatin. An identical volume of saline solution (154 mM) was administered by
intraperitoneal injection to control group mice.
Assay of gene expression by RNA-seq. Total RNA was extracted from mouse
kidney, liver, lung, and spleen using TRIzol RNA extraction (Thermo Fisher Sci-
entiﬁc). After phase separation, RNA was puriﬁed using the PureLink RNA Mini
Kit (Thermo Fisher Scientiﬁc). Puriﬁed total RNA sample was treated with DNase I
(TURBO DNA-freeTM kit, Ambion Inc.) to remove traces of DNA. RNA libraries
were prepared using the NEBNext Ultra RNA library prep kit (Illumina) according
to the manufacturer’s instructions. In brief, total RNA starting with 1 μg was poly-
A selected, fragmented by random priming and then converted to cDNA using
ProtoScript II reverse transcriptase. The cDNA was then end-repaired, adenylated
and ligated with Illumina sequencing adaptors. Libraries from all samples were
pooled and sequenced using an Illumina HiSeq 4000 with 50-bp pair-end read.
Assay of DNA damage by Damage-seq and immuno-slot blot. In Damage-seq
assay15, genomic DNA was extracted using PurLink Genomic DNA kit (Thermo).
Ultrasonic fragmented genomic DNAs were puriﬁed using an equal volume of
HighPrep PCR beads (MagBio). Puriﬁed DNA (~1 µg) was used for End-repair and
dA-tailing and adaptor ligation (NEBNext Ultra II DNA Library Prep Kit) fol-
lowing manufacturer’s instructions. Following IP (immunoprecipitation) with
0.4 µg anti-cisplatin antibody (ab 103261, Abcam), the DNA was primer extended
in the presence of 30 pmol Bio3U (biotin elongation primer, 5′-bio-AGAGTG/dU/
GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3′) using NEBNext Q5 Hot
Start HiFi PCR Master Mix. After undamaged DNA strands were captured by
20 pmol (2 µL) of SH oligo (SH, Subtractive hybridization, 5′-bio-NNGACTGGT
TCCAATTGAAAGTGCTCTTCCG-SpC-3′), DNAs were puriﬁed using phenol-
chloroform extraction and ethanol precipitation. The DNA was then ligated to a
second adaptor ligation using T4 DNA ligase HC (Thermo) at 16 °C overnight.
After quality check, the DNA samples were puriﬁed with HighPrep PCR beads, and
ligated DNAs were PCR ampliﬁed by NEBNext Ultra II PCR Master Mix with
NEBNext Multiplex Oligos for Illumina (New England Biolabs). The PCR libraries
were puriﬁed with HighPrep PCR beads. Libraries from all samples were pooled
and sequenced using an Illumina HiSeq 4000 with 50-bp single-end read.
For the immuno-slot blot assay, a total of 200 ng genomic DNA was spotted
onto a PVDF membrane (Immun-Blot LF, Bio-Rad Laboratories Inc.) using a
transfer device (Bio-Dot SF, 160BR 08600, Bio-Rad Laboratories Inc.). After
blocking in 5% skim milk, the membrane was incubated with cisplatin antibody
(1:2000 dilution in 5% milk) overnight at 4 °C. The membrane was washed three
times with 1X TBST (0.2% Tween 20), then incubated with secondary (1:5000, anti-
rat HRP, GE Health Care, NA 935V) antibody for 1 h at room temperature. After
washing the membrane, signals were detected with Clarity Western ECL
chemiluminescent reagent (Bio-Rad Laboratories Inc.). In order to visualize the
total DNA signal from each individual spot as an internal control, the membrane
was washed three times with 1X TBST, and incubated with anti-DNA antibody
(1:10,000, anti-DNA antibody, MAB 3034, Millipore Sigma) overnight at 4 °C. The
membrane was washed three times, then incubated with secondary antibody
(1:5000, anti-mouse HRP, GE Health Care, NA 931V) for 1 h at room temperature,
then the same washing and signal detection steps were repeated.
Assay of DNA excision repair by XR-seq. In XR-seq assay18, 4 h after treatment
of mice with cisplatin, the mice were killed by carbon dioxide exposure, the kid-
neys, liver, lung, and spleen were removed and washed extensively with cold
phosphate buffered saline (PBS), and then homogenized in 5 ml ice-cold PBS until
the plunger moved freely (around 15–20 strokes based on the source of tissue)
using Telfon homogenizer. The homogenized tissues were transferred into 50 ml
tubes and washed three times with ice-cold PBS at 2500 rpm for 4 min. After last
wash, the cell pellets were resuspended in 5 ml ice-cold buffer A (25 mM HEPES,
pH 7.9, 100 mM KCI, 12 mM MgCl2, 0.5 mM EDTA, 2 mM DTT, 12.5% glycerol
and 0.5% NP-40) and incubate on ice for 10 min. Then, cells were lysed by an ice-
cold Dounce homogenizer with 70 strokes using tight plunger. The chromatin
fraction was then pelleted by centrifugation for 30 min at 14,000 rpm at 4 °C in a
1.7 ml microcentrifuge tubes. The pelleted chromatin fragment was kept at −20 °C
for further DNA extraction and damage-seq library preparation. The supernatants
containing low molecular DNA-protein fragments (excision products) were
immunoprecipitated with anti-TFIIH (p89 antibody (G-10, sc-271500, and p62
antibody (H-10, sc-25329), Santa-Cruz Biotechnology), and ligated to adaptors on
the both ends. After a second immunoprecipitation with 2.5 μg cisplatin-speciﬁc
antibody, the Pt-DNA adducts were reversed by incubating in NaCN (200 mM)
overnight at 65 °C. Then the damage-free DNAs were ampliﬁed by PCR to get XR-
seq libraries and sequenced using an Illumina HiSeq 4000 with 50-bp single-end
read.
ENCODE data. Epigenomic data across four mouse organs were downloaded from
the ENCODE portal as bed ﬁles and visualized using the UCSC browser (Sup-
plementary Table 1). All of the ENCODE data were generated from mice without
cisplatin treatment, which enabled us to study DNA damage and repair within the
context of pre-existing epigenomic proﬁles. While the effect of cisplatin treatment
on epigenomic proﬁles would be of interest, here we focused on the genes that do
not show signiﬁcant up- or down-regulation after cisplatin treatment across all
organs tested. In addition, most of the ENCODE data were generated using 8-
week-old young adult mice (Supplementary Table 1).
Bioinformatic processing for Damage-seq, XR-seq, and RNA-seq. For Damage-
seq, cutadapt51 was used to remove reads adaptor sequence GACTGGTTCCAA
TTGAAAGTGCTCTTCCGATCT at the 5′-end, which are from the undamaged
strands15. For XR-seq, cutadapt51 was used to trim reads with adaptor sequence
TGGAATTCTCGGGTGCCAAGGAACTCCAGTNNNNNNACGATCTCGTAT
GCCGTCTTCTGCTTG at the 3′-end and discard untrimmed reads16. For both
Damage-seq and XR-seq, BWA52 was used for read alignment, and Picard tools
(http://broadinstitute.github.io/picard/) was used for ﬁltering, sorting, deduplica-
tion, and indexing. Post-alignment ﬁltering steps were adopted using Rsamtools
(http://bioconductor.org/packages/Rsamtools/) for XR-seq and Damage-seq,
respectively. For XR-seq, we only keep reads that (i) have mapping quality >20, (ii)
are of length 21–31 bp, and (iii) have Pt-d(GpG) dinucleotide sequence 5–8 bp
upstream from the 3′-end of the reads. For Damage-seq, we only kept reads that (i)
had mapping quality >20, (ii) had Pt-d(GpG) dinucleotide sequence 1–2 bp
upstream from the 5′-end of the reads. Reads from the TS and NTS strands were
separated using known gene annotations for mm10 by ENSEMBL.
For RNA-seq, reads were aligned using STAR53, followed by a ﬁltering step to
remove: (i) reads with mapping quality less than 20, (ii) read pairs with unexpected
orientations and >500 Kb mapping distance between the read pair, and (iii) reads
that were mapped to >10 positions in the genome. Read counts for each gene were
obtained using FeatureCounts54, followed by DESeq231 for differential expression
analysis, with a threshold of 0.4 on log fold change and a false discovery rate cutoff
of 0.05. Gene ontology analysis was performed using http://geneontology.org, with
a false discovery rate cutoff of 0.05. GO enrichment results were further processed
with REViGO55 and visualized by Cytoscape56, as shown in Supplementary
Figure 14.
Quality control and data normalization. We use RPKM for within-sample nor-
malization for the RNA-seq data and adjust for sample-speciﬁc sequencing depth
and gene-speciﬁc number of GG dinucleotides for XR-seq and Damage-seq. For
DESeq2 differential expression analysis, we use all genes as input to the software.
To investigate the relationship between gene expression, chromatin states and
DNA damage and repair, we adopted a stringent quality control (QC) procedure
and only retained genes that: (i) had at least one sample with expression; (ii) had
matched gene ID across all sequencing platforms; (iii) had at least ten GG dinu-
cleotides in the TS or the NTS; (iv) were less than 100 Kb; and (v) have at least 20
reads in total across samples for RNA-seq, Damage-seq, and XR-seq, respectively.
Batch effect was adjusted using ComBat30 with batch as a known covariate.
For data normalization, we also took the ratio of the reads from the TS and the
NTS, TS/(TS+NTS), to remove biases and artifacts that are shared between the two
DNA stands (i.e., library size, number of di-guanines/gene length, cisplatin delivery
efﬁciency (Supplementary Figure 7)), as well as other gene-speciﬁc biases, such as
sequencing bias and antibody pull-down efﬁciency, etc. The ratio is bound between
0 and 1 and sheds light upon how TCR and GR interplay.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
The data reported in this paper have been deposited in the Gene Expression
Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession number
GSE117167). All code used in this paper is available at https://github.com/
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yuchaojiang/damage_repair. All other relevant data are available from the corre-
sponding authors on request.
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